Technology

MEDIPOST CO., LTD. CEO Oh Won-il Receives Presidential Commendation on “Medicine Day” for His Contributions to the Development of Cartistem

Led the First Commercialization of Cord Blood Stem Cell Therapies in Korea in 2012 Cumulative Number of Treated Patients Reaches 38,000… Company Seeks Overseas Expansion Through Phase 3 Clinical Trials in the U.S. and Japan

NA EUN-KYUNG
2026-11-19 11:45:02
[Edaily Reporter NA EUN-KYUNG ] Oh Won-il, CEO of MEDIPOST CO., LTD.(078160), received a Presidential Commendation for his contributions to the development and commercialization of “CartiStem,” a stem cell therapy derived from umbilical cord blood.

MEDIPOST CO., LTD. announced on the 19th that CEO Oh received the Presidential Commendation at the “40th Pharmacy Day” ceremony held on the 18th in Gangnam-gu, Seoul.

Oh Won-il, CEO of MEDIPOST CO., LTD., received the Presidential Commendation at the “40th Pharmacy Day” event held in Gangnam-gu, Seoul, on the 18th. (Photo: MEDIPOST CO., LTD.)


Pharmacy Day commemorates the enactment of the Pharmacy Act in 1953 and was designated as a statutory commemorative day in 2021. The Ministry of Food and Drug Safety holds an annual ceremony to honor individuals who have contributed to pharmaceutical safety management and the development of the pharmaceutical industry.

CEO Oh is a board-certified specialist in clinical laboratory medicine who graduated from Seoul National University College of Medicine. After serving as a professor at Seoul Asan Medical Center and Samsung Seoul Hospital, he joined MEDIPOST CO., LTD. in 2004 as the director of the Biotechnology Research Institute. He subsequently oversaw the research and development of stem cell therapies and was appointed CEO in 2022.

One of his most notable achievements is the commercialization of Cartistem, a treatment for knee osteoarthritis. Cartistem is a medication that uses allogeneic mesenchymal stem cells extracted from donated umbilical cord blood to repair damaged knee cartilage. It is used to treat knee cartilage defects in patients with osteoarthritis caused by degenerative conditions or repeated trauma.

MEDIPOST CO., LTD. received domestic marketing authorization for Cartistem from the Ministry of Food and Drug Safety in January 2012. This marked the world’s first commercialization of an allogeneic stem cell therapy derived from umbilical cord blood. Unlike methods that involve collecting and culturing a patient’s own cells, Cartistem is distinguished by its ability to produce the product using cells obtained from a donor’s umbilical cord blood.

According to the company, Cartistem has been used in approximately 38,000 patients over the past 14 years since its domestic approval. Building on the commercialization experience gained in Korea, MEDIPOST CO., LTD. is now pursuing entry into the U.S. and Japanese markets.

In Japan, the company has completed a Phase 3 clinical trial targeting patients with knee osteoarthritis. In the U.S., it received approval from the Food and Drug Administration (FDA) for its Phase 3 clinical trial plan in February of this year and has begun clinical development. This is part of the process to expand the domestically approved product into major overseas markets.

In addition to Cartistem, CEO Oh led the development of “SMUP-Cell,” a next-generation stem cell platform. MEDIPOST CO., LTD. is also developing follow-up drug candidates, such as an injectable osteoarthritis treatment, using this technology.

CEO Oh stated, “I would like to thank our employees and medical staff who have worked together to ensure that Cartistem can improve patients’ lives,” adding, “We will do our utmost to ensure that Korea’s cutting-edge biopharmaceuticals gain recognition in the global market through global clinical trials and the development of our follow-up pipeline.”

Economy

Corporation

IT·Science

Economy

“Coin Collection Exceeds 1 Trillion”… Dunamu Launches Appreciation Event

Dunamu, the operator of the digital asset (virtual asset) exchange Upbit, is holding a customer appreciation event.On the 19th, Dunamu announced that it has organized two special events—the “Coin Coll…
2026-11-19 11:53:38

Corporation

After Enhancing the Flavor and Adding Protein… TakeFit Sees Sales Jump 48%

NamyangDairyProducts(003920)’s protein brand “TakeFit” saw its cumulative sales for the third quarter of this year increase by 48.3% compared to the same period last year. Analysts attribute this grow…
2026-11-19 09:14:40